

NEWS RELEASE

Mumbai, 10th November, 2015

Marksans Pharma Limited, an emerging global pharmaceutical company, has reported today its financial performance for the Q2 FY 2015-16 and for the half year ended 30th September 2015.

Performance Highlights.

Marksans Consolidated Q2 FY 2015-16, Performance Highlights.

- Consolidated Total Revenue grew by 21.38% to Rs. 2555.43 Mn from Rs. 2105.39 Mn in Q2 FY 2015-16.
- EBITDA grew to Rs. 513.81 Mn for the quarter. EBITDA margin was at 20.11% for the quarter.
- Consolidated Net Profit before Tax was Rs. 430.34 Mn for the Q2 FY 2015-16.
- Consolidated Net Profit after Tax was Rs. 348.71 Mn for the Q2 FY 2015-16.
- Consolidated Post –Tax profits up by 11.90% as against same quarter in the previous year.

Marksans Consolidated Half Year Financial Results Highlights.

- Consolidated Total Revenue grew by 13.33% to Rs. 4680.01 Mn from Rs. 4129.55 Mn in the First Half of FY 2015-16.
- EBITDA grew by 10.70% to Rs. 1037.87 Mn for First Half of FY 2015-16 as against Rs. 937.55 during previous year. EBITDA margin was at 22.18% for the half year.
- Consolidated Net Profit after Tax was Rs. 663.38 Mn for the First Half of FY 2015-16 as against Rs. 566.32 in the previous year.
- Consolidated Post–Tax profits up by 17.14% as against the same period in the previous year.

Business Highlights

- US & North America formulation business grew by 107.20% to Rs. 1575.52 Mn from Rs. 760.40 Mn during First Half of FY 2015-16. US revenue contributed 33.66% of the total revenue.

CIN : L24110MH1992PLC066364



www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011

E-mail: info@marksanspharma.com



Marksans Pharma Ltd.

- Europe and UK formulation revenue was at Rs. 2433.08 Mn during First Half of FY 2015-16. Europe and UK business contributed 51.99% of the total revenue.
- Australia & NZ business grew by 10.01% to Rs. 452.18 Mn from Rs. 411.05 Mn during First Half of FY 2015-16.
- Company achieved revenue of Rs. 219.23 Mn from Rest of World (Asia, Africa & CIS) formulation business during First Half of FY 2015-16.

Revenue Figures - Consolidated

	INR in Million	
	First Half FY 2015-16	First Half FY 2014-15
US & North America – Formulations	1575.52	760.40
Europe & UK – Formulations	2433.08	2711.92
Australia & NZ – Formulations	452.18	411.05
Rest of World (ROW) – Asia, Africa & CIS Formulations	219.23	246.18
Consolidated Revenue from operations	4680.01	4129.55

About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK MHRA, Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Cough & Cold, Pain management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Limited

11th Floor, "GRANDEUR", Veera Desai Extension Road, Oshiwara, Andheri (West)
Mumbai – 400 053, India

Tel:- +91 22 4001 2000, Fax:- +91 22 4001 2011.



CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com